Tianda Pharmaceuticals (SEHK:455) - Prezzo delle azioni, notizie e analisi

La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

455 Panoramica delle azioni

455 analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	5/6
Dividendi	0/6

Premi

Analisi del rischio

Gli utili sono diminuiti del 53.9% all'anno negli ultimi 5 anni

Non ha una capitalizzazione di mercato significativa ( HK$458M )

Tianda Pharmaceuticals Limited Concorrenti

Wai Yuen Tong Medicine Holdings

SEHK:897

HK$235.1m

Lansen Pharmaceutical Holdings

SEHK:503

HK$750.6m

Fusen Pharmaceutical

SEHK:1652

HK$709.7m

Jilin Province Huinan Changlong Bio-pharmacy

SEHK:8049

HK$801.2m

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Tianda Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azione	HK$0.23
Massimo di 52 settimane	HK$0.28
Minimo di 52 settimane	HK$0.18
Beta	0.013
1Variazione di 1 mese	-13.21%
Variazione a 3 mesi	-4.96%
Variazione di 1 anno	9.00%
3Variazione a 3 anni	21.05%
Variazione a 5 anni	8.49%
Variazione dall'IPO	-60.68%

Notizie e aggiornamenti recenti

Tianda Pharmaceuticals Limited (HKG:455) Investors Are Less Pessimistic Than Expected

Aug 16

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Jun 20

Recent updates

Tianda Pharmaceuticals Limited (HKG:455) Investors Are Less Pessimistic Than Expected

Aug 16

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Jun 20

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

Mar 27

Rendimenti per gli azionisti

	455	HK Pharmaceuticals	HK Mercato
7D	5.0%	1.7%	1.3%
1Y	9.0%	10.8%	4.2%

Ritorno vs Industria: 455 ha avuto una performance inferiore rispetto al Hong Kong Pharmaceuticals che ha registrato un rendimento 10.8 % nell'ultimo anno.

Rendimento vs Mercato: 455 ha superato il mercato Hong Kong che ha restituito 4.6 % nell'ultimo anno.

Volatilità dei prezzi

Is 455's price volatile compared to industry and market?
455 volatility
455 Average Weekly Movement	9.0%
Pharmaceuticals Industry Average Movement	5.0%
Market Average Movement	6.3%
10% most volatile stocks in HK Market	13.2%
10% least volatile stocks in HK Market	3.4%

Prezzo delle azioni stabile: 455 non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 9% ) di 455 è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1992	863	Alan Fang	www.tiandapharma.com

Tianda Pharmaceuticals Limited, insieme alle sue controllate, si occupa di ricerca e sviluppo, produzione e vendita di prodotti farmaceutici, biotecnologici e sanitari nella Cina continentale, a Hong Kong e in Australia. Fornisce farmaci cinesi, farmaci chimici, prodotti biologici e sanitari e apparecchi medici che coprono le aree terapeutiche cardio-cerebrovascolare, pediatrica, antinfluenzale e respiratoria, antinfettiva, disintossicante, antitumorale e altre. L'azienda offre i suoi prodotti sanitari con i marchi Herb Valley e Tuokang.

Tianda Pharmaceuticals Limited Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Tianda Pharmaceuticals con la sua capitalizzazione di mercato?
455 statistiche fondamentali
Capitalizzazione di mercato	HK$494.51m
Guadagni(TTM)	-HK$24.15m
Ricavi(TTM)	HK$532.09m

0.9x

Rapporto P/S

-20.5x

Rapporto P/E

455 è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
455 Conto economico (TTM)
Ricavi	HK$532.09m
Costo del fatturato	HK$276.56m
Profitto lordo	HK$255.53m
Altre spese	HK$279.69m
Guadagni	-HK$24.15m

Ultimi guadagni dichiarati

Dec 31, 2023

Prossima data di guadagno

Aug 28, 2024

Utile per azione (EPS)	-0.011
Margine lordo	48.02%
Margine di profitto netto	-4.54%
Rapporto debito/patrimonio netto	17.7%

Come si è comportato 455 nel lungo periodo?

Vedi performance storica e confronto

Dividendi

1.1%

Rendimento attuale del dividendo

-23%

Rapporto di remunerazione

455 Panoramica delle azioni

Premi

Analisi del rischio

Tianda Pharmaceuticals Limited Concorrenti

SEHK:897

HK$235.1m

SEHK:503

HK$750.6m

SEHK:1652

HK$709.7m

SEHK:8049

HK$801.2m

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Tianda Pharmaceuticals Limited Provides Unaudited Consolidated Earnings Guidance for the Six-Month Period from 1 January 2024 to 30 June 2024

Tianda Pharmaceuticals Limited (HKG:455) Investors Are Less Pessimistic Than Expected

Tianda Pharmaceuticals Limited to Report First Half, 2024 Results on Aug 28, 2024

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Tianda Pharmaceutical Technology (Zhuhai) Co., Ltd. Receives Drug Registration Approval of Ibuprofen Suspension

Tianda Pharmaceuticals Limited Approves Final Dividend

Recent updates

Tianda Pharmaceuticals Limited Provides Unaudited Consolidated Earnings Guidance for the Six-Month Period from 1 January 2024 to 30 June 2024

Tianda Pharmaceuticals Limited (HKG:455) Investors Are Less Pessimistic Than Expected

Tianda Pharmaceuticals Limited to Report First Half, 2024 Results on Aug 28, 2024

Is Tianda Pharmaceuticals (HKG:455) Using Debt In A Risky Way?

Tianda Pharmaceutical Technology (Zhuhai) Co., Ltd. Receives Drug Registration Approval of Ibuprofen Suspension

Tianda Pharmaceuticals Limited Approves Final Dividend

Now 24% overvalued after recent price rise

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 07, 2024

Now 21% overvalued after recent price rise

There's Reason For Concern Over Tianda Pharmaceuticals Limited's (HKG:455) Massive 26% Price Jump

New major risk - Revenue and earnings growth

Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended 31 December 2023

Tianda Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Mar 26, 2024

New minor risk - Share price stability

Now 26% undervalued

Estimating The Fair Value Of Tianda Pharmaceuticals Limited (HKG:455)

Now 29% undervalued

Tianda Pharmaceuticals Limited Announces Executive Changes, Effective 29 August 2023

Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Interim Period Ended June 30, 2023

Tianda Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 28% undervalued

Tianda Pharmaceuticals Limited (SEHK:455) entered into an equity transfer agreement to acquire 45% stake in Yunnan Mengsheng Pharmaceutical Co., Ltd from Yunnan Linuo Biotechnology Co., Ltd. for HKD 23.5 million.

Tianda Pharmaceuticals Limited Announces Board Changes

Now 25% undervalued after recent price drop

Is Tianda Pharmaceuticals (HKG:455) Using Debt Sensibly?

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 27, 2023

Full year 2022 earnings released: HK$0.025 loss per share (vs HK$0.011 loss in FY 2021)

Executive Chairman & MD recently bought HK$2.7m worth of stock

Executive Chairman & MD recently bought HK$448k worth of stock

Executive Chairman & MD recently bought HK$52k worth of stock

Tianda Pharmaceuticals (HKG:455) Has Debt But No Earnings; Should You Worry?

First half 2023 earnings released: HK$0.008 loss per share (vs HK$0.008 loss in 1H 2022)

Tianda Pharmaceuticals Limited to Report First Half, 2023 Results on Nov 25, 2022

Less than half of directors are independent

Executive Chairman & MD recently bought HK$129k worth of stock

Tianda Pharmaceuticals Limited Declares Final Dividend

Tianda Pharmaceuticals Limited, Annual General Meeting, Aug 25, 2022

Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended March 31, 2022, Payable on September 08, 2022

Full year 2022 earnings released

Tianda Pharmaceuticals Limited Proposes Special Dividend for the Year Ended 31 March 2022

Tianda Pharmaceuticals Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Less than half of directors are independent

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Non-Executive Director Lee George Lam has left the company

Does Tianda Pharmaceuticals (HKG:455) Have A Healthy Balance Sheet?

Full year 2021 earnings released: HK$0.013 loss per share (vs HK$0.001 profit in FY 2020)

Full year 2021 earnings released: HK$0.013 loss per share (vs HK$0.001 profit in FY 2020)

Tianda Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Year Ended 31 March 2021

First half 2021 earnings released: HK$0.007 loss per share

Is Tianda Pharmaceuticals (HKG:455) Using Too Much Debt?

First half 2021 earnings released: HK$0.007 loss per share

Tianda Pharmaceuticals Limited to Report First Half, 2021 Results on Nov 27, 2020

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Tianda Pharmaceuticals Limited Riepilogo dei fondamenti

0.9x

-20.5x